ArticleJACC. CardioOncology2023
Cancer-Associated Thrombosis: Trends in Clinical Features, Treatment, and Outcomes From 2001 to 2020.
Article in JACC. CardioOncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02832245 (Computerized Registry of Patients With Venous Thromboembolism), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study.European heart journal. Cardiovascular pharmacotherapy · 2024Trial
- Global burden of venous thromboembolism: incidence and outcome estimates of deep-vein thrombosis and pulmonary embolism.Nature reviews. Cardiology · 2026Review
- Revisiting bleeding risk in cancer-associated thrombosis: Beyond the asian paradox.Journal of thrombosis and thrombolysis · 2026Article
- Rising prevalence of venous thromboembolism in gastrointestinal cancers: a nationwide analysis of 205 million hospitalizations, 2016-2022.Journal of gastrointestinal oncology · 2026Article
- Venous thromboembolism prevention and treatment with factor XI/XIa inhibitors: current status and future perspectives.Journal of thrombosis and thrombolysis · 2026Review
- Venous thromboembolism in patients with breast, ovarian, and uterine cancer. A comparative analysis from the Registro Informatizado Enfermedad TromboEmbólica registry.Research and practice in thrombosis and haemostasis · 2026Article
- Causes of death after surgery among cancer patients: a population-based cohort study.International journal of surgery (London, England) · 2026Article
- Comparative safety of enoxaparin versus other low-molecular-weight heparins in cancer-associated venous thromboembolism: a real-world cohort study from RIETE.Research and practice in thrombosis and haemostasis · 2025Article
- Perioperative anticoagulation reduces the incidence of venous thromboembolism in patients undergoing gastrointestinal surgery.World journal of gastrointestinal surgery · 2025Article
- Mortality risk after cancer-related venous thromboembolism has decreased over the last three decades: the HUNT and Tromsø studies.Haematologica · 2025Article
- Prevention of Peripherally Inserted Central Catheter (PICC)-Associated Vein Thrombosis in Cancer: A Narrative Review.Biomedicines · 2025Review
- Thrombosis, Translational Medicine, and Biomarker Research: Moving the Needle.Journal of the American Heart Association · 2025Review
- A mouse model of deep vein thrombosis by inferior vena cava hypoperfusion using ameroid constrictors.Scientific reports · 2025Article
- Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study.Research and practice in thrombosis and haemostasis · 2025Article
- The Conundrum of Cancer-Associated Thrombosis: Lesson Learned from Two Intriguing Cases and Literature Review.Diseases (Basel, Switzerland) · 2024Article
- Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis.Journal of pharmaceutical policy and practice · 2024Article
- Cancer-Associated Venous Thromboembolism: Changes Over the Past 20 Years.JACC. CardioOncology · 2023Article
- Sex-specific Risks in Lung Cancer-Associated Thrombosis: Focus on Female Patients.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
- Venous Thromboembolism in Women with Breast and Gynaecological Cancers: What Do We Know and What Should We Do?Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite advances in cancer and venous thromboembolism (VTE) management, the epidemiology of cancer-associated thrombosis management over time remains unclear. Objectives: We analyzed data from the RIETE (Registro Informatizado de la Enfermedad Trombo Embólica) registry spanning 2001 to 2020 to investigate temporal trends in clinical characteristics and treatments for cancer-associated thrombosis. Methods: Using multivariable survival regression, we examined temporal trends in risk-adjusted rates of symptomatic VTE recurrences, major bleeding, and death within 30 days after incident VTE. Results: Among the 17,271 patients with cancer-associated thrombosis, there was a progressive increase in patients presenting with pulmonary embolism (from 44% in 2001-2005 to 55% in 2016-2020; Conclusions: In this multicenter study of cancer patients with VTE, there was a decline in thrombotic, hemorrhagic, and fatal events from 2001 to 2020. (Registro Informatizado de la Enfermedad Trombo Embólica [RIETE]; NCT02832245).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.